IFRX Latest Press Releases

-- November 6, 2026 --

InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan Globe Newswire 7:30 AM

-- November 3, 2026 --

InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day Globe Newswire 7:00 AM

-- October 27, 2026 --

InflaRx Announces November Investor Events Globe Newswire 7:30 AM

-- October 22, 2026 --

InflaRx Highlights Izicopan's Therapeutic Potential at Kidney Week 2026 Globe Newswire 12:00 PM

-- October 2, 2026 --

InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026 Globe Newswire 7:30 AM

-- October 1, 2026 --

InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development Globe Newswire 7:30 AM

-- September 21, 2026 --

InflaRx to Host Virtual Capital Markets Day Globe Newswire 7:30 AM

-- August 20, 2026 --

InflaRx Announces Participation in September Investor Conferences Globe Newswire 7:30 AM

-- August 6, 2026 --

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones Globe Newswire 7:30 AM

-- July 30, 2026 --

InflaRx to Report Second Quarter 2026 Results on August 6, 2026 Globe Newswire 7:30 AM

-- June 30, 2026 --

InflaRx Assessing Feasibility of Broadened Strategy for ANCA-Associated Vasculitis in Europe Following EMA Recommendation on Tavneos Globe Newswire 7:30 AM

Market Data Delayed 15 Minutes